Novel Gallium Imaging in Hepatocellular Carcinoma

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present study is to validate the uptake of novel, positron emitting radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging modality for identification of HCC lesions in the liver. The investigators intend to use the results of this preliminary study to fuel further studies in the utility of 68Ga-citrate PET/CT for HCC treatment monitoring.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rutgers, The State University of New Jersey
• Collaborator: Radiological Society of North America
• Treatments: Citric Acid; Gallium citrate

Criteria

Inclusion Criteria:

• At least one biopsy-confirmed or Liver Imaging Reporting and Data System (LI-RADS)- 5 HCC lesion, diagnosed within the past 6 weeks.

• Lesion size greater than or equal to 3cm

• At least one triple-phase CT or MRI of the liver prior to medical or surgical therapy

Exclusion Criteria:

• Pregnant or breast-feeding women.

• Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.

• Inability to consent

• Prior medical or surgical therapy for HCC, including chemoembolization, radiofrequency ablation, and lobectomy

• Known or suspected hypersensitivity to metals or gallium